Biomedical Engineering Reference
In-Depth Information
Table 10.4
Published Clinical Studies on ALA- and MAL-PDT for Nodular Basal Cell Carcinoma
Light Source
(Wavelength in
nm)
Incubation Period
(hr)
# Lesions Treated
(# Patients)
Reference
ALA Preparation
Location of nBCC
Response Rate
Follow-up (mo)
Fijan (264) (1995)
1× ALA-PDT in
combination with
desferrioxamine
(no lesion
preparation
specifi ed),
repeated after
3-6 mo if required
Face, scalp, trunk,
and extremities
Not specifi ed
22 (32)
Halogen lamp with
a red fi lter
32% CR after
1 treatment,
59% after
2 treatments
3-20
Calzavara-Pinton
(132) (1995)
Various cutaneous
malignancies.
ALA20% emulsion
ALA-PDT repeated
EOD until clinical
disappearance
Head, trunk, and
limbs
6-8
30
Argon dye laser
(630)
1-mo lesion CR
(histologically
controlled) : 61%
33% Recurrence
after median of
29 mo
24-36
Thissen (151) (2000)
1× ALA-PDT using
20% ALA cream
and DMSO
(lesion
preparation)
Not specifi ed
6 Occluded
24 (23)
Red light (630-635
nm, 120 J/cm
2
,
100 mW/cm
2
)
3-6 mo lesion CR:
92%
5% recurrence after
median of 17 mo
17
Wang (141) (2001)
20% ALA cream
1× ALA-PDT ×
Cryotherapy 2×
freeze-thaw
cryotherapy,
repeat at 12 wk, if
required
Head and neck,
trunk, and limbs
6 Occluded
49 nBCC
(25 treated
with ALA-PDT)
39 sBCCs (22
treated with
ALA-PDT)
Frequency doubled
Nd:YAG laser
pumping a dye
laser (635 nm, 60
J/cm
2
, 80 ± 20
mW cm
2
)
12 mo histologically
recurrences: 13%
for ALA-PDT vs.
21% for
cryotherapy
12
Christensen (154)
(2009)
1 or 2× ALA-PDT
(7 days apart)
using 20% ALA
cream and
DMSO (lesion
preparation)
Face, scalp, trunk,
and extremities
3 Occluded
36 nBCC
24 superfi cial BCC
Broadband halogen
light source
(550-700 nm,
150-230 mW/
cm
2
)
3 mo CR (sBCC +
nBCC): 91%, 17%
of nBCC recurred
after 72 mo
72
